help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Mulligan, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Mulligan, T.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 10 3506-3514
Copyright © 1999 by The Endocrine Society


From the Clinical Research Centers

Joint Basal and Pulsatile Hypersecretory Mechanisms Drive the Monotropic Follicle-Stimulating Hormone (FSH) Elevation in Healthy Older Men: Concurrent Preservation of the Orderliness of the FSH Release Process: A General Clinical Research Center Study1

J. D. Veldhuis, A. Iranmanesh, L. M. Demers and T. Mulligan

Division of Endocrinology, Department of Internal Medicine, National Science Foundation Center for Biological Timing, University of Virginia Health Sciences Center (J.D.V.), Charlottesville, Virginia 22908; the Endocrine Section, Medical Service, Salem Veterans Affairs Medical Center (A.I.), Salem, Virginia 24153; the Department of Pathology, Pennsylvania State University Medical School (L.M.D.), Hershey, Pennsylvania 17033-0850; and Geriatrics Medicine, Hunter Holmes McGuire Veterans Affairs Medical Center (T.M.), Richmond, Virginia 23249

Address all correspondence and requests for reprints to: Dr. J. D. Veldhuis, Division of Endocrinology, Department of Internal Medicine, Box 202, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908. E-mail: jdv{at}virginia.edu


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
To appraise the neuroendocrine mechanisms that underlie a selective (monotropic) elevation of serum FSH concentrations in healthy older men, we sampled blood in 11 young (ages 21–34) and 8 older men (ages 62–72) men every 2.5 min overnight. Serum FSH concentrations were quantitated in an automated, high-sensitivity, chemiluminescence-based assay. Rates of basal and pulsatile FSH secretion were estimated by deconvolution analysis, and the orderliness of the FSH release process via quantitated the approximate entropy statistic. Statistical analysis revealed that healthy older men manifest dual neuroendocrine hypersecretory mechanisims; specifically, a 2-fold increase in the basel (nonpulsatile) FSH secretion rate, and a concurrent 50% amplification of FSH secretory burst mass (and amplitude). The regularity or orderliness of ad seriatim FSH release is preserved in older individuals. We postulate that higher basel FSH secretion in older men is a consequence of reduced testosterone negative feedback, whereas amplified FSH secretory burst mass reflects net enhanced stimulation of gonadotrope cells by endogenous FSH secretagogues (e.g. GnRH and/or activin). The foregoing specific mechanisms driving heightened FSH secretion in older men contrast with the lower-amplitude pulsatility and more disorderly patterns of LH release in the same individuals. Thus, the present data illuminate an age-dependent disparity in the disruption of FSH neuroregulation in the aging male.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ALTHOUGH a single decapeptide, GnRH, stimulates both LH and FSH release acutely in experimental animals and humans (1, 2), the regulation of LH and FSH secretion can be dissociated in a variety of pathophysiological conditions. For example, in the rodent, sheep, or lagomorph, discrepant release of LH and FSH emerges in several experimental contexts, e.g. in different sex steroid hormone milieus; after GnRH antagonist administration; in response to localized hypothalamic electrical stimulation or neurochemical lesioning; after inhibin immunoneutralization or replacement; and under variable frequency pulsatile GnRH drive (2, 3, 4, 5, 6, 7). Analogously, in the human, discordant secretion of LH and FSH becomes evident in the course of puberty, during escalating GnRH pulse frequency stimulation in men and women, after GnRH antagonist administration, in idiopathic oligospermia, within the normal menstrual cycle, and as one of the earlier neuroendocrine features of male and female reproductive aging (8, 9, 10, 11, 12, 13, 14, 15).

Although pulsatile FSH release is less visibly evident and analytically tractable than pulsatile LH secretion (9, 16), recent in vitro and in vivo experiments document directly both pulsatile and basal (nonpulsatile or constitutive) components of FSH secretion (5, 7, 17, 18, 19). The mechanisms that control the pulsatile vs. basal modes of FSH release probably differ, as several glycoprotein hormones, such as inhibin and activin, can selectively suppress or stimulate basal FSH secretion over hours (2), whereas GnRH evokes a rapid pulse of FSH secretion over minutes mimicking the burst-like mode of LH release (1).

To date, no clinical studies to our knowledge have explored the pathophysiological regulation of basal vs. pulsatile FSH release in healthy aging. This deficiency results in part from the analytical challenge of simultaneously quantifying basal and pulsatile gonadotropin secretion, especially without prior knowledge of relevant hormone-specific elimination rates (20). To the latter end, we recently performed bolus and steady state iv infusions of highly purified human FSH in hypopituitary men (followed by RIA, immunoradiometric assay (IRMA), and bioassay of the serum FSH disappearance curves) to calculate directly FSH’s biexponential kinetics (21). Given such half-life estimates, we could here apply half-life constrained multiparameter deconvolution analysis to evaluate the individual and joint contributions of basal and pulsatile FSH secretion to the selective FSH elevation observed in healthy older men (22, 23).

We hypothesized, first, that the monotropic rise in serum FSH concentrations in normal, unmedicated, ambulatory, and clinically eugonadal older men arises mechanistically from a preponderant increase in basal FSH secretion, with an unchanged (or reduced) young adult pulsatile mode of FSH release. Secondly, we postulated that the orderliness of FSH release patterns as quantified by approximate entropy is age independent. We tested these ideas by frequent (2.5-min) blood sampling overnight in 11 young and 8 older healthy men, followed by FSH chemiluminescence assay.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Clinical protocol

Eleven healthy young men, aged 21–34 yr, and eight older men, aged 62–72 yr, were recruited from the University of Virginia, Richmond, and Salem communities for study in the General Clinical Research Center after provision of written informed consent approved by the institutional review board. Each volunteer first underwent 1 night of adaptation to the study unit, followed by overnight blood sampling at 2.5-min intervals from a forearm vein. A long venous catheter was used to sample from an adjacent room to avoid disturbing the patient during sleep. Volunteers were healthy, ambulatory, and unmedicated men without acute or chronic illness, weight changes (2 kg within 10 days), or recent (within 2 weeks) transmeridian (more than three time zones) travel. There was no evidence by screening laboratory tests, physical examination, or medical history of hepatic, renal, hematological, metabolic, or endocrine diseases. Baseline serum concentrations of immunoreactive LH, FSH, PRL, GH, TSH, T4, resin T3 binding, testosterone, and estradiol were all unremarkable for age (12, 24).

Assays

Serum concentrations of FSH (or LH) were assayed in each sample (or a pool) via an automated random access chemiluminescence-based immunoassay (180, Chiron Corp., East Walpole, MA) using WHO Second International Reference Preparation 94/632 (or 80/552). Independent studies demonstrated a linear correlation between FSH (or LH) concentrations measured in this manner and duplicate values determined independently by IRMA (r >= 0.899; n = 18; P < 10-5) (25). The within-assay coefficients of variation (CVs) were less than 6.5%, and the between-assay CVs less than 9.0%. The former was used to calculate within-sample SD estimates for deconvolution analysis. All samples from an individual were analyzed together to eliminate interassay variability.

Serum inhibin B (Inhibin-B Dimer Assay Kit, Serotec, Kidlington, UK), total and bioavailable testosterone, LH, GH, TSH, dehydroepiandrosterone sulfate, cortisol, T4, insulin-like growth factor I (IGF-I), and IGF-binding protein-3 concentrations were assayed in overnight pools in each volunteer via commercially available kits using enzyme-linked immunosorbent assay (ELISA), RIA, or IRMA, as described previously (12, 24, 26, 27, 28). Estradiol was assayed by a commercially available double antibody RIA (Third-Generation DSL-39100, Diagostics Systems Laboratories, Inc., Webster, TX) with less than 7% cross-reactivity with estrone and less than 0.45% with less potent estrogens. Sensitivity was 0.6 pg/mL with the lowest standard at 1.5 pg/mL, linearity to 150 pg/mL, and an ED50 of 20 pg/mL. The range in normal men is reported as undetectable to 44 pg/mL (manufacturer’s data; n = 57 men). The intra- and interassay CVs were 2.4–6.5% and 3.7–9.9%, respectively, with 85–109% recovery (added estradiol, 11–120 pg/mL).

Deconvolution analysis

Deconvolution analysis with an a priori half-life constraint was applied to estimate pulsatile FSH secretion from the overnight serum FSH concentration time series, using techniques described previously (22, 23, 29, 30). We estimated basal FSH secretion and concurrently the number, duration, mass, amplitude, and frequency of statistically significant FSH secretory bursts (P < 0.05 vs. zero amplitudes by joint statistical confidence intervals) using previously published two-component FSH elimination kinetics (21). In particular, the mean rapid phase (initial) half-life of FSH was 110 min, the mean slower component was 620 min, and their fractional amplitude (of the slower component taken as a ratio of total disappearance) was 0.39 (21). FSH kinetics were assumed to be invariant throughout the sampling interval and independent of age. Deconvolution measures included the mass of FSH secreted per burst (integral of the computed secretory event), amplitude of the FSH secretory burst (maximal rate of FSH secretion attained within a release episode), half-duration (time elapsed in minutes at half-maximal secretory burst amplitude), frequency (number of FSH secretory pulses observed per sampling session), and interpulse interval (time in minutes separating the center of consecutive FSH secretory bursts). Basal FSH secretory rates are expressed as the amount (international units) of FSH secreted per unit distribution volume (liters) per unit time (minutes). Total FSH production overnight represents the sum of pulsatile (mean pulse mass multiplied by FSH burst number) and basal FSH secretion (mean FSH secretory rate multiplied by duration of sampling interval).

Approximate entropy (ApEn)

ApEn is a family of scale-independent statistics used to assess the orderliness or serial regularity of hormone patterns on a sample by sample basis; hence, ApEn quantitates variability that is subordinate to pulsatile or circadian rhythms. Any particular ApEn statistic is a single, finite, nonnegative, real number assigned as an ensemble value to a hormone profile, with larger values corresponding to greater relative randomness of the serial measures. ApEn measures technically the logarithmic likelihood that short runs of data patterns that are similar remain similar on the next incremental comparison (31). Two principal input parameters, namely m and r, are fixed to compute ApEn from vector sequences constructed from the observed data, where m represents the window length of consecutive hormone measurement pattern, and r is the tolerance for testing subpattern recurrence. To maintain scale invariance, r is typically fixed as a percentage or fraction of the between-sample SD of each time series, e.g. 20%, and m is fixed as a value of 1 or 2 denoting consecutive data vectors of length one or two data points. For the FSH series analyzed here, we calculated ApEn values with r = 0.2 and m = 1, and hence, the designation, ApEn (1, 20%). This provides an appropriate statistic for assessing subpattern reproducibility in data series of this length (14, 32).

Statistics

Statistical comparisons were made by a two-tailed unpaired Student’s t test for mean serum FSH concentrations, and the Wilcoxon (rank sum) unpaired nonparametric test for specific deconvolution measures due to their non-Gaussian distributions. Secretory measures are reported as the mean ± SEM (median). Linear correlations were determined by Pearson’s coefficient. P < 0.05 was considered statistically significant.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
As illustrated in Fig. 1AGo for three young and three older men, serum FSH concentrations overnight were visually pulsatile and superimposed upon apparently time- invariant baseline release. FSH secretion profiles calculated by deconvolution analysis using (previously published) biexponential FSH kinetics are illustrated in Fig. 1BGo.



View larger version (26K):
[in this window]
[in a new window]
 
Figure 1. Illustrative serum FSH concentration profiles (A) and deconvolution-calculated FSH secretory rates (B) in three young (left column) and three older (right column) healthy men sampled at 2.5-min intervals overnight. Deconvolution analysis was carried out using two-component FSH kinetics reported earlier based on iv infusions of highly purified human urinary FSH injected in hypopituitary middle-aged men (21 ). FSH was measured in a chemiluminescence-based assay. Vertical bars denote interpolated dose-dependent within-assay SDs (see Materials and Methods).

 
As summarized in Fig. 2Go, mean overnight serum FSH concentrations were approximately 2-fold higher in the group of older men compared to those in their young counterparts (P = 0.0066). Integrated values were comparably age dependent (not shown). In contrast, overnight (pooled) serum TSH, estradiol, inhibin B, and GH concentrations were age invariant (Table 1Go). Serum IGF-I, IGF-binding protein-1, T3, and dehydroepiandrosterone sulfate concentrations were lower in older men, whereas that of cortisol was higher (Table 1Go). LH concentrations averaged as follows: older, 3.8 ± 0.41 IU/L; young, 3.4 ± 0.33 IU/L (P = NS). Figure 2Go depicts the corresponding individual mean LH values in all 19 volunteers.



View larger version (15K):
[in this window]
[in a new window]
 
Figure 2. Individual men’s mean serum FSH (top) and LH (bottom) concentrations determined by automated chemiluminescence assay in blood collected at 2.5-min intervals overnight in 11 young and 8 older healthy men. Numerical values shown are the group means ± SEM. The P value was determined by unpaired two-tailed Student’s t testing.

 

View this table:
[in this window]
[in a new window]
 
Table 1. Selected (pooled) serum hormone measurements in young and older men sampled every 2.5 min overnight

 
Total, bioavailable, and percent bioavailable testosterone are shown in the 8 older and 11 young men in Fig. 3Go. Bioavailable, but not total, testosterone showed a significant age contrast (P < 0.01). In a chemiluminescent assay of total serum testosterone (26), values averaged 523 ± 40 (young) and 425 ± 48 ng/dL (older; P = NS); and, in another RIA (27), values averaged 470 ± 39 (young) and 397 ± 36 ng/dL (older; P = NS).



View larger version (16K):
[in this window]
[in a new window]
 
Figure 3. Individual men’s mean (pooled) overnight serum total (top), bioavailable (middle), and percent bioavailable (bottom) testosterone concentrations. Data are rendered as defined in Fig. 2Go.

 
Deconvolution analysis revealed discrete FSH secretory bursts in young and older individuals. FSH secretory burst amplitude (maximal height of the secretory impulse) and mass (integral of the calculated secretory event) were each higher in the older men. In particular, the former was 2-fold higher in older individuals: older, 0.090 ± 0.008 (0.065); young, 0.042 ± 0.007 (0.040) IU/L/min (P < 0.05). Correspondingly, the FSH secretory burst mass (computed amount of FSH secreted per unit distribution volume per pulse) was greater at 0.91 ± 0.15 (0.83) IU/L in the older compared with 0.59 ± 0.08 (0.47) in the young men (P < 0.05).

The age contrast in FSH secretory burst amplitude/mass was specific, as the half-duration of FSH secretory bursts was similar in both age groups [14 ± 2.1 (12) min in young and 9.3 ± 1.9 (10) min in older subjects], as was the mean number of FSH secretory bursts overnight [5.0 ± 0.51 (5) in young and 5.3 ± 0.53 (5) in older men; P = NS]. The FSH intersecretory pulse interval also did not differ with age, averaging in young 81 ± 6.2 (72) vs. in older men 70 ± 8 (67) min.

Basal FSH secretory rates were elevated 2-fold in older individuals at 0.0042 ± 0.0009 (0.0031) vs. 0.0021 ± 0.0004 (0.0016) IU/L·min in young volunteers (P < 0.01).

Overnight basal, pulsatile, and total (summed basal and pulsatile) FSH secretion values in young and older men are compared in Fig. 4Go. For each measure, older men (compared to their young counterparts) secreted more FSH (P = 0.040 to P < 0.01). Expressed as a percentage of the total FSH secretion, the pulsatile component was similar at 75 ± 4.4% (75) in young vs. 73 ± 4.9% (79) in older subjects.



View larger version (13K):
[in this window]
[in a new window]
 
Figure 4. Comparisons between overnight pulsatile (top), basal (middle), and total (lower) FSH secretion in 11 young and 8 older men sampled every 2.5 min. Quantitation of serum FSH concentrations was by automated chemiluminescence assay (see Materials and Methods). The basal FSH secretion rate was calculated using a biexponential FSH disappearance model measured earlier in hypopituitary men infused with highly purified urinary-derived human FSH (21 ). Basal FSH secretion is expressed in units of mass (international units; Second WHO International Reference Preparation) secreted per unit distribution volume (liters) per unit time (minutes) or overnight. Data are the mean ± SEM, with statistical analysis by two-tailed unpaired Student’s t testing.

 
Table 1Go gives mean FSH ApEn values in the two groups of older and young men, which were not significantly different.

Figure 5Go highlights the negative linear correlations between basal FSH secretion rates and serum estradiol or bioavailable testosterone, but not inhibin B, concentrations. In contrast, FSH burst mass did not show any correlation with estradiol, bioavailable testosterone, or inhibin B. Mean serum FSH concentrations correlated negatively with serum estradiol (r = -0.59; P = 0.020).



View larger version (21K):
[in this window]
[in a new window]
 
Figure 5. Correlation of basal FSH secretion rates with serum estradiol and bioavailable testosterone concentrations in 19 men (11 young and 8 older). P values apply to the Pearson correlation coefficients.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Only limited studies to date have appraised the neuroregulation of pulsatile FSH secretion (10, 11, 12, 16, 33, 34, 34), and virtually no analyses have quantified the individual contributions of pulsatile and basal secretion to total FSH release in vivo (32). Understanding the partitioning of total FSH release into its pulsatile and basal components is likely to be important, in view of mounting evidence for distinct pathophysiological control of these separate components by endocrine, autocrine, and paracrine feedback. To address this issue, we used a multiparameter deconvolution method with a priori experimental estimates of biexponential FSH elimination kinetics (22, 23, 30), which allowed us to quantitate FSH secretory bursts and estimate basal FSH secretion rates simultaneously. Secondly, we applied the approximate entropy statistic as a scale-invariant measure of the orderliness of (nonpulsatile) FSH release patterns. And, third, we related basal and/or pulsatile FSH secretion rates to overnight pooled estimates of estradiol, bioavailable testosterone, and inhibin B (ELISA) concentrations.

The mean (overnight) serum FSH concentration was approximately 2-fold higher in the older (than young) men studied here. This measurement by chemiluminescence assay agrees with most earlier clinical reports of elevated circulating immunoreactive FSH concentrations in older individuals (2), but contrasts with diminished circulating FSH levels in the older male rodent (35, 36). Thus, in the human, either primary gonadoprival states or older age (e.g. in both men and peri- and postmenopausal women) will evoke elevated serum FSH concentrations, whether assessed by chemiluminescence (present data), RIA, IRMA, or bioassay (9, 11, 12, 37, 38, 39, 40). Gonadotropin changes in the healthy older men studied here were monotropic, as FSH rose, but there was no associated increase in the mean serum LH concentration. Other hormone concentrations were altered in the expected manner in healthy, unmedicated, ambulatory, unstressed older males, but how or whether such changes contribute to isolated FSH hypersecretion is not known.

By deconvolution analysis, we quantitated a 2-fold amplification of the basal FSH secretory rate overnight in older men, assuming identical FSH kinetics in both age groups. This age-related augmentation could reflect partial withdrawal of gonadal negative feedback control of FSH release (13, 41). For example, the presently measured decrease in bioavailable (but not total) serum testosterone concentrations in the older subjects might plausibly account for the rise in basal FSH secretion. Indeed, linear correlation analysis (n = 19 men) disclosed a significant negative relationship between serum bioavailable testosterone concentrations and basal FSH secretion rates. In addition, augmented FSH secretion rates in older men might be mediated by reduced (intra-)pituitary actions of follistatin and/or inhibin, and/or greater intrapituitary drive of gonadotrope cell FSH biosynthesis, e.g. by activin (2). The last speculation would be consistent with activin’s ability to stimulate FSH release in the rat in vitro and in the monkey in vivo (4). Other regulatory factors might also modulate the synthesis of FSH (3, 4, 17). However, independently of the (various) biochemical inputs to gonadotrope cells, our inference of a 2-fold heightened basal FSH secretion rate in older men indicates for the first time to our knowledge that age can control the nonpulsatile mode of pituitary FSH secretion.

Sustained pulsatile secretion of FSH (and LH) requires an intermittent, rather than continuous, GnRH pulse stimulus (1, 2, 42, 43). Conversely, GnRH antagonist infusion will significantly reduce serum FSH (and LH) concentrations, blunt FSH secretory pulse amplitude, and abolish the acute surge-like release of FSH triggered by combined estrogen and progesterone administration in older women (8, 44, 45, 46, 47). Down-regulation experiments with GnRH agonistic analogs also support a role for episodic endogenous GnRH release in maintaining the pulsatile discharge of FSH (2). In contrast to GnRH’s (feedforward) drive of FSH production, negative feedback by gonadal sex steroid hormones will oppose GnRH-stimulated FSH release in the sheep, rat, and human (2). For example, a pulsatile GnRH infusion in men fails to stimulate progressive serum FSH increases when serum (aromatizable) androgen concentrations rise (48). Conversely, a continuous iv infusion of estradiol suppresses FSH secretory burst mass and inhibits FSH release stimulated by an (exogenous) iv bolus of GnRH (10, 11, 12). Thus, FSH secretion appears to require relevant stimulatory signals, such as intermittent GnRH and/or other agonists (feedforward drive) and, conversely, is susceptible to negative modulation by inhibitory feedback inputs. In accordance with the latter idea, we report here that serum bioavailable testosterone (an aromatizable androgen) and estradiol concentrations both correlate negatively with basal FSH secretion rates. Of interest, neither serum sex steroid nor inhibin B concentrations correlated with FSH secretory pulse mass. Thus, a plausible speculation is that aging results in accentuated net gonadotrope cell basal FSH release, on the one hand, and attenuated feedback inhibition of FSH release by estradiol and bioavailable testosterone, on the other hand. In contrast, serum inhibin B concentrations measured by ELISA were similar in both age cohorts, perhaps reflecting the excellent health of the older volunteers studied here, the specificity of the ELISA used, the number of subjects studied, and/or our 6- to 8-h overnight pooling of sera for specific inhibin B assay.

In both young and older men, the nonaromatizable androgen, 5{alpha}-dihydrotestosterone, infused continuously iv over 3 days suppresses FSH secretory burst frequency, but not FSH pulse mass (10, 11). Conversely, antiandrogen treatment often increases gonadotropin (LH) pulse frequency (49, 50). Thus, we reason that older men’s enhanced FSH secretory pulse mass with no attendant rise in burst frequency is probably not due to selective withdrawal of androgen receptor-mediated negative feedback. Rather, as estrogen reduces FSH pulse mass without altering FSH peak frequency (2), we speculate that the low bioavailable testosterone concentrations measured in older men indirectly raise FSH secretory burst mass by limiting substrate availability for intrapituitary estrogen formation.

Whereas the frequency of low amplitude LH pulses tends to rise (24, 26, 51), and conversely, that of higher amplitude LH peaks tends to fall (52) in older men, the present results show that overnight FSH pulse number is not higher in elderly individuals. The neuroendocrine mechanism underlying this discrepancy between LH and FSH pulse frequencies in aging men is not known. One plausible conjecture is that aging results in a partial loss of GnRH-FSH pulse coupling, perhaps analogously to reduced GnRH-LH pulse linkage in uremia (53). A second hypothesis is an age-related disparity in feedback and/or feedforward factors that regulate FSH (vs. LH) release, e.g. preferential (net) augmentation of gonadotrope cell FSH synthesis, release, or storage, which thereby would enlarge FSH secretory burst mass in older men. Consistent with this view of enhanced availability of pituitary FSH is the consistently heightened release of FSH after near-maximally effective single dose GnRH injection in older men (37, 39, 54, 55) and a recent report of elevated activin A in older (albeit premenopausal) women (56).

Direct hypothalamo-pituitary venous blood sampling in the horse and sheep have recently documented significant basal as well as pulsatile modes of FSH release (5, 18, 57). Whereas similar invasive blood sampling in the human is not ethically practicable, our finding of amplified FSH secretory burst mass (and amplitude) in older individuals would make FSH pulse detection in the peripheral blood relatively more reliable in older than in young subjects. Thus, our analyses should not be vulnerable to a preferential type II statistical error in FSH pulse detection in older (compared with young) individuals.

As appraised via the approximate entropy statistic, the serial orderliness of LH release deteriorates significantly in older men, whether evaluated by 10-min blood sampling over 24 h (14) or by 2.5-min blood sampling overnight (58). In contrast, the present intensive sampling schedule demonstrates the lack of any erosion of pattern regularity of FSH release with aging. One plausible clinical hypothesis to explicate this age-related contrast in the relative orderliness of LH and FSH release is that aging (or one of its covariates) differentially attenuates the GnRH-driven subcellular signaling, synthesis, packaging, and/or secretion of LH (vs. FSH) by gonadotrope cells (17), thus eliciting more disorderly patterns of LH (but not FSH) release in older subjects. Alternatively, FSH release is stabilized by other (less age-dependent) factors.

Whether blood removal rates for FSH are altered in hypopituitary individuals (22) or healthy older men is not known definitively. This is a plausible conjecture, as multiple FSH glycosylation products with potentially different half-lives exist (59, 60). Heterogeneity of FSH molecules is evident in heterologous kinetic assays [e.g. human serum FSH extracts injected into hypophysectomized mice (61)] as well as by deconvolution analysis of FSH release stimulated by GnRH pulses at different stages of the normal menstrual cycle (62). In the case of LH, reduction of gonadal sex steroid negative feedback promotes the accumulation in blood of more acidic LH isoforms, which typically exhibit more prolonged in vivo half-lives due to their greater posttranslational sialic acid composition (60, 63). An unexpected (and as yet unreported) increase in the endogenous FSH half-life in older men would require less FSH secretion per unit distribution volume to achieve equivalently elevated serum FSH concentrations in older individuals, which would thus tend to falsely mimic enhanced basal FSH secretion analytically (20). Against this postulate is the observation that endogenous FSH half-lives calculated by deconvolution analysis after GnRH-stimulated FSH release in older men are not increased (12, 32, 54). On the other hand, as the mass of FSH secreted per burst is computed as an incremental rise above basal secretion, any hypothetically prolonged FSH half-life in older individuals would not account for their higher calculated FSH secretory burst mass.

In summary, we have investigated the neuroendocrine mechanisms underlying the monotropic elevation in serum FSH concentrations in healthy older men. The older men studied here overnight exhibited young adult serum concentrations of LH, total testosterone, estradiol, and inhibin B, but reduced serum bioavailable testosterone. Deconvolution analysis with earlier published biexponential FSH kinetics revealed a doubling of mean serum FSH concentrations in older men, which originated mechanistically from their nearly 2-fold elevated basal (nonpulsatile) FSH secretion rate combined with a 50% rise in FSH secretory burst mass. These dual hypersecretory features in aging men were specific, as no differences were apparent in FSH secretory pulse duration, interpulse interval, or frequency. The bipartite mechanisms of FSH hypersecretion suggest an age-related augmentation of both time-invariant basal (putatively only minimally GnRH-dependent) and pulsatile (presumptively largely GnRH-driven) FSH release. These new observations on the mechanisms of heightened FSH release in older men contrast with earlier appraisals of LH secretory dynamics, which often show a decline in LH secretory burst mass (and amplitude) with a reciprocal rise in LH pulse frequency in aging. Using the ApEn statistic, we further note that the quantifiable orderliness of sample to sample FSH (unlike LH) release patterns remains unaltered in older men. We conclude that reproductive aging in men provides a physiological paradigm of dissociated LH and FSH regulation in three primary respects: 1) preferential elevation of basal FSH secretion rates, 2) opposite changes in FSH (increased) and LH (decreased) secretory pulse amplitude (mass), and 3i) divergent age-related relative preservation of the orderliness of FSH (vs. LH) release. The exact hypothalamo-pituitary-gonadal feedforward and feedback control mechanisms that govern such age-related distinctions in the regulated output of the two primary gonadotropins will require further clinical study.


    Acknowledgments
 
We thank Patsy Craig for her skillful preparation of the manuscript; Paula P. Azimi for the deconvolution and other data analysis, management, and graphics; Brenda Grisso and James Garmey for performance of the assays; and Sandra Jackson and the expert nursing staff at the University of Virginia General Clinical Research Center for conduct of the clinical research protocols.


    Footnotes
 
1 This work was supported in part by NIH Grant MO1-RR-00847 (to the General Clinical Research Center of the University of Virginia Health Sciences Center), Research Career Development Award 1-KO4-HD-00634 (to J.D.V.), the National Science Foundation Center for Biological Timing (NSF Grant DIR 89–20162), the NIH U-54 Specialized Cooperative Centers Program in Reproductive Research (HD-28934) (J.D.V.), NIH NIA Grant RO1-AG-14799–01 (to J.D.V.), and Veterans Affairs Merit Review Research Funds (to T.M.). Back

Received March 26, 1999.

Revised May 25, 1999.

Accepted July 8, 1999.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Schally AV, Arimura A, Kastin AJ, et al. 1971 Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 173:1036–1038.[Abstract/Free Full Text]
  2. Veldhuis JD. 1991 The hypothalamic pituitary-testicular axis. In: Yen SSC, Jaffe RB, eds. Reproductive endocrinology. Philadelphia: Saunders; 409–459.
  3. McCann SM, Mizunuma H, Samson WK, Lumpkin MD. 1983 Differential hypothalamic control of FSH secretion: a review. Psychoneuroendocrinology. 8:299–308.[CrossRef][Medline]
  4. Ying S. 1988 Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of FSH. Endocr Rev. 9:267–282.[Medline]
  5. Pincus SM, Padmanabhan V, Lemon W, Randolph J, Midgley Jr AR. 1998 Follicle-stimulating hormone is secreted more irregularly than luteinizing hormone in both humans and sheep. J Clin Invest. 101:1318–1324.[Medline]
  6. Majumdar JJ, Mikuma N, Ishwad PC, Winters SJ, Attardi BJ, Perera AD, Plant TM. 1995 Replacement with recombinant human inhibin immediately after orchidectomy in the hypophysiotropically clamped male rhesus monkey (Macaca mulatta) maintains follicle-stimulating hormones (FSH) secretion and FSHß messenger ribonucleic acid levels at precastration values. Endocrinology. 136:1969–1977.[Abstract]
  7. Culler MD, Negro-Vilar A. 1987 Pulsatile follicle-stimulating hormone secretion is independent of luteinizing hormone-releasing hormone (LHRH): pulsatile replacement of LHRH bioactivity in LHRH-immunoneutralized rats. Endocrinology. 120:2011–2021.[Abstract]
  8. Hall JE, Brodie TD, Badger TM, et al. 1988 Evidence for differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of GnRH antagonist. J Clin Endocrinol Metab. 67:524–531.[Abstract]
  9. Booth RAJ, Weltman JY, Yankov VI, et al. 1996 Mode of pulsatile FSH secretion in gonadal-hormone sufficient and deficient women. J Clin Endocrinol Metab. 81:3208–3214.[Abstract]
  10. Urban RJ, Dahl KD, Padmanabhan V, Beitins IZ, Veldhuis JD. 1991 Specific regulatory actions of dihydrotestosterone and estradiol on the dynamics of FSH secretion and clearance in man. J Androl. 12:27–35.[Abstract/Free Full Text]
  11. Urban RJ, Dahl KD, Lippert MC, Veldhuis JD. 1992 Endogenous androgen and estrogen modulate immunoradiometric and bioactive FSH secretion and clearance in young and elderly men. J Androl. 13:579–586.[Abstract/Free Full Text]
  12. Veldhuis JD, Iranmanesh A, Samojlik E, Urban RJ. 1997 Differential sex-steroid negative feedback regulation of pulsatile follicle-stimulating hormone secretion in healthy older men: deconvolution analysis and steady state sex steroid hormone infusions in frequently sampled healthy older individuals. J Clin Endocrinol Metab. 82:1248–1254.[Abstract/Free Full Text]
  13. Foresta C, Bordon P, Rossato M, Mioni R, Veldhuis JD. 1997 Specific linkages among luteinizing hormone, follicle stimulating hormone, and testosterone release in the peripheral blood and human spermatic vein: evidence for both positive (feed-forward) and negative (feedback) within-axis regulation. J Clin Endocrinol Metab. 82:3040–3046.[Abstract/Free Full Text]
  14. Pincus SM, Veldhuis JD, Mulligan T, Iranmanesh A, Evans WS. 1997 Effects of age on the irregularity of LH and FSH serum concentrations in women and men. Am J Physiol. 273:E989–E995.
  15. Sherman BM, West JH, Korenman SG. 1976 The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab. 42:629–636.[Abstract]
  16. Dunkel L, Alfthan H, Stenman UH, Tapanainen P, Perheentupa J. 1990 Pulsatile secretion of LH and FSH in prepubertal and early pubertal boys revealed by ultrasensitive time-resolved immunofluorometric assay. Pediatr Res. 27:215–219.[Medline]
  17. Meriggiola MC, Dahl KD, Mather JP, Bremner WJ. 1994 Follistatin decreases activin-stimulated FSH secretion with no effect on GnRH-stimulated FSH secretion in prepubertal male monkeys. Endocrinology. 134:1967–1970.[Abstract]
  18. Padmanabhan V, McFadden K, Mauger DT, Karssch FJ, Midgley Jr AR. 1997 Neuroendocrine control of follicle-stimulating hormone (FSH) secretion. I. Direct evidence for separate episodic and basal components of FSH secretion. Endocrinology. 138:424–432.[Abstract/Free Full Text]
  19. Farnworth PG, Robertson DM, de Kretser DM, Burger HG. 1988 Effects of 31 kilodalton bovine inhibin on follicle-stimulating hormone and luteinizing hormone in rat pituitary cells in vitro: actions under basal conditons. Endocrinology. 122:207–213.[Abstract]
  20. Veldhuis JD, Evans WS, Johnson ML. 1995 Complicating effects of highly correlated model variables on nonlinear least-squares estimates of unique parameter values and their statistical confidence intervals: estimating basal secretion and neurohormone half-life by deconvolution analysis. Methods Neurosci. 28:130–138.[CrossRef]
  21. Urban RJ, Padmanabhan V, Beitins I, Veldhuis JD. 1991 Metabolic clearance of human follicle-stimulating hormone assessed by radioimmunoassay, immunoradiometric assay, and in vitro Sertoli cell bioassay. J Clin Endocrinol Metab. 73:818–823.[Abstract]
  22. Veldhuis JD, Carlson ML, Johnson ML. 1987 The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA. 84:7686–7690.[Abstract/Free Full Text]
  23. Veldhuis JD, Johnson ML. 1992 Deconvolution analysis of hormone data. Methods Enzymol. 210:539–575.[Medline]
  24. Veldhuis JD, Urban RJ, Lizarralde G, Johnson ML, Iranmanesh A. 1992 Attenuation of luteinizing hormone secretory burst amplitude is a proximate basis for the hypoandrogenism of healthy aging in men. J Clin Endocrinol Metab. 75:52–58.
  25. Iranmanesh A, Mulligan T, Veldhuis JD. 1999 Mechanisms subserving the physiological nocturnal relative hypoprolactinemia of healthy older men: dual decline in prolactin secretory burst mass and basal release with preservation of pulse duration, frequency, and interpulse interval. J Clin Endocrinol Metab. 84:1083–1090.[Abstract/Free Full Text]
  26. Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD. 1995 Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: possible Leydig cell desensitization to endogenous LH signaling–a clinical research center study. J Clin Endocrinol Metab. 80:3025–3031.[Abstract/Free Full Text]
  27. Manni A, Pardridge WM, Cefalu W, Nisula B, Bardin CW, Santner SHJ, Santen RJ. 1985 Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab. 61:705–710.[Abstract]
  28. Groome NP, Illingworth PJ, O’Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. 1996 Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab. 81:1401–1405.[Abstract]
  29. Johnson ML, Veldhuis JD. 1995 Evolution of deconvolution analysis as a hormone pulse detection method. Methods Neurosci. 28:1–24.
  30. Veldhuis JD, Johnson ML. 1995 Specific methodological approaches to selected contemporary issues in deconvolution analysis of pulsatile neuroendocrine data. Methods Neurosci. 28:25–92.
  31. Pincus SM. 1995 Quantifying complexity and regularity of neurobiological systems. Methods Neurosci. 28:336–363.
  32. Veldhuis JD, Iranmanesh A, Urban RJ. 1997 Primary gonadal failure in men selectively amplifies the mass of follicle stimulating hormone (FSH) secreted per burst and increases the disorderliness of FSH release: reversibility with testosterone replacement. Int J Androl. 20:297–305.
  33. Veldhuis JD, King JC, Urban RJ, Rogol AD, Evans WS, Kolp LA, Johnson ML. 1987 Operating characteristics of the male hypothalamo-pituitary-gonadal axis: pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. J Clin Endocrinol Metab. 65:929–941.[Abstract]
  34. Urban RJ, Johnson ML, Veldhuis JD. 1991 In vivo biological validation and biophysical modeling of the sensitivity and positive accuracy of endocrine peak detection. II. The FSH pulse signal. Endocrinology. 128:2008–2014.[Abstract]
  35. Blackman MR, Mukherjee A, Tsitouras PD, Harman SH. 1985 Decreased in vitro secretion of LH, FSH, and free {alpha}-subunits by pituitary cells from old male rats. Am J Physiol. 249:E145–E151.
  36. Peng MT, Hsu HK, Pi WP, Wu KM, Liao CF, Wan WCM. 1983 Pattern of reproductive hormone secretion and disappearance rates of LH and FSH in senile male rats. Gerontology. 29:32–40.[Medline]
  37. Harman SM, Tsitouras PD, Costa PT, Blackman MR. 1982 Reproductive hormones in aging men. II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 54:547–551.[Abstract]
  38. Madersbacher S, Stulnig T, Huber LA, Schonitzer D, Dirnhofer S, Wick G, Berger P. 1993 Serum glycoprotein hormones and their free alpha-subunit in a healthy elderly population selected according to the SENIEUR protocol. Analyses with ultrasensitive time resolved fluoroimmunoassays. Mech Ageing Dev. 71:223–233.[CrossRef][Medline]
  39. Snyder PJ, Reitano JF, Utiger RD. 1975 Serum LH and FSH responses to synthetic gonadotropin releasing hormone in normal men. J Clin Endocrinol Metab. 41:938–945.[Abstract]
  40. Morley JE, Kaiser FE, Perry IIi HM, et al. 1997 Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metab Clin Exp. 46:410–413.
  41. Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. 1987 The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab. 65:1118–1125.[Abstract]
  42. Veldhuis JD, Evans WS, Rogol AD, Kolp L, Thorner MO, Stumpf P. 1986 The pituitary self-priming actions of gonadotropin- releasing hormone: kinetics of estradiol’s potentiating effects on GnRH-facilitated LH and FSH release in healthy post-menopausal women. J Clin Invest. 77:1849–1856.
  43. Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC, Shupnik MA. 1991 A pulsatile GnRH stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology. 128:509–517.[Abstract]
  44. Dahl KD, Pavlou SN, Kovacs WJ, Hsueh AJW. 1986 The changing ratio of serum bioactive to immunoreactive follicle-stimulating hormone in normal men following treatment with a potent gonadotropin releasing hormone antagonist. J Clin Endocrinol Metab. 63:792–794.[Abstract]
  45. Kolp LA, Pavlou SN, Urban RJ, Rivier JC, Vale WW, Veldhuis JD. 1992 Abrogation by a potent GnRH antagonist of the estrogen/progesterone-stimulated surge-like release of LH and FSH in postmenopausal women. J Clin Endocrinol Metab. 75:993–997.[Abstract]
  46. Urban RJ, Pavlou SN, Rivier JE, Vale WW, Dufau ML, Veldhuis JD. 1990 Suppressive actions of a gonadotropin-releasing hormone (GnRH) antagonist on LH, FSH, and prolactin release in estrogen-deficient postmenopausal women. Am J Obstet Gynecol. 162:1255–1260.[Medline]
  47. Davis MR, Veldhuis JD, Rogol AD, Dufau ML, Catt KJ. 1987 Sustained inhibitory actions of a potent antagonist of gonadotropin-releasing hormone in postmenopausal women. J Clin Endocrinol Metab. 64:1268–1274.[Abstract]
  48. Goodman RL, Pickover SM, Karsch FJ. 1981 Ovarian feedback control of follicle-stimulating hormone in the ewe: evidence for selective suppression. Endocrinology. 108:772–777.[Abstract]
  49. Urban RJ, Davis MR, Rogol AD, Johnson ML, Veldhuis JD. 1988 Acute androgen receptor blockade increases luteinizing-hormone secretory activity in men. J Clin Endocrinol Metab. 67:1149–1155.[Abstract]
  50. Veldhuis JD, Urban RJ, Dufau ML. 1994 Differential responses of biologically active LH secretion in older vs. young men to interruption of androgen negative feedback. J Clin Endocrinol Metab. 79:1763–1770.[Abstract]
  51. Mulligan TM, Iranmanesh A, Veldhuis JD. Failed restitution of Leydig cell testosterone secretion despite full normalization of pulsatile release by two weeks of exogenous pulsatile GnRH pump/infusion therapy in older men. Proc of the 80th Annual Meet of The Endocrine Soc. 1998, A127.
  52. Vermeulen A, Deslypere JP, Kaufman JJ. 1989 Influence of antiopioids on luteinizing hormone pulsatility in aging men. J Clin Endocrinol Metab. 68:68–72.[Abstract]
  53. Schaefer F, Daschner M, Veldhuis JD, Oh J, Qadri F, Scharer K. 1994 In vivo alterations in the gonadotropin releasing hormone (GnRH) pulse generator and the secretion and clearance of luteinizing hormone in the uremic castrate rat. Neuroendocrinology. 59:285–296.[CrossRef][Medline]
  54. Zwart AD, Urban RJ, Odell WD, Veldhuis JD. 1996 Contrasts in the gonadotropin-releasing dose-response relationships for luteinizing hormone, follicle-stimulating hormone, and alpha-subunit release in young vs. older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis. Eur J Endocrinol. 135:399–406.[CrossRef][Medline]
  55. Winters SJ, Troen P. 1982 Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. J Clin Endocrinol Metab. 55:560–565.[Abstract]
  56. Reame NE, Wyman TL, Phillips DJ, de Kretser DM, Padmanabhan V. 1998 Net increase in stimulatory input resulting from a decrease in inhibin B and an increase in activin A may contribute in part to the rise in follicular phase follicle-stimulating hormone of aging cycling women. J Clin Endocrinol Metab. 83:3302–3307.[Abstract/Free Full Text]
  57. Irvine CH, Alexander SL. 1994 The dynamics of gonadotrophin-releasing hormone, LH and FSH secretion during the spontaneous ovulatory surge of the mare as revealed by intensive sampling of pituitary venous blood. J Endocrinol. 140:283–295.[Abstract/Free Full Text]
  58. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD. 1996 Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad Sci USA. 93:14100–14105.[Abstract/Free Full Text]
  59. Bogdanove EM, Campbell GTR, Peckman WD. 1984 FSH pleomorphism in the rat–regulation by gonadal steroids. Endocr Rev. 1:87–99.
  60. Beitins IZ, Padmanabhan V. 1991 Bioactivity of gonadotrophins. Endocrinol Metab Clin North Am. 20:85–120.[Medline]
  61. Wide L, Wide M. 1984 Higher plasma disappearance rate in the mouse for pituitary follicle-stimulating hormone of the young women compared to that of men and elderly women. J Clin Endocrinol Metab. 54:426–429.
  62. Zambrano E, Olivares A, Mendez JP, Guerrero L, Veldhuis JD, Ulloa-Aguirre A. 1995 Dynamics of basal and GnRH-releasable serum FSH charge isoform distribution throughout the menstrual cycle. J Clin Endocrinol Metab.80:1647–1656.
  63. Dufau ML, Veldhuis JD. 1987 Pathophysiological relationships between the biological and immunological activities of luteinizing hormone. In: Burger HG, eds. Bailliere’s clinical endocrinology and metabolism. Philadelphia: Saunders; 153–176.



This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, P. Y. Takahashi, P. D. Roebuck, and J. D. Veldhuis
Age or Factors Associated with Aging Attenuate Testosterone's Concentration-Dependent Enhancement of the Regularity of Luteinizing Hormone Secretion in Healthy Men
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4077 - 4084.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Iranmanesh and J. D. Veldhuis
Combined Inhibition of Types I and II 5 {alpha}-Reductase Selectively Augments the Basal (Nonpulsatile) Mode of Testosterone Secretion in Young Men
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4232 - 4237.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
A. M. Matsumoto
Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men
J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
J. A. Schnorr, M. J. Bray, and J. D. Veldhuis
Aromatization Mediates Testosterone's Short-Term Feedback Restraint of 24-Hour Endogenously Driven and Acute Exogenous Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone and Follicle-Stimulating Hormone Secretion in Young Men
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2600 - 2606.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Mulligan, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Mulligan, T.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals